No Data
No Data
Outperforming the Large Cap in the past 4 months! Hong Kong stocks for Innovative Drugs are gaining strength again, with Institutions expecting that the pharmaceutical main theme may run through the entire year.
① Hong Kong stocks of Innovative Drugs are strengthening again, which Bullish catalysts are Institutions focusing on? ② The Biomedical Index has outperformed the Large Cap for the past four months; how strong has its performance been this year?
AI empowers the FDA! Drug approvals hit the 'fast-forward' button, and a large number of pharmaceutical companies may welcome a 'Gold' period.
The USA Food and Drug Administration (FDA) announced an accelerated plan on Thursday to fully implement AI applications across all subsidiary institutions by June 30, aiming to significantly expedite the approval process for new pharmaceuticals.
IMMUNOTECH-B: 2024 ANNUAL REPORT
IMMUNOTECH-B (06978): Yu Xiaohui has been appointed as a non-executive Director and a member of the Audit Committee.
IMMUNOTECH-B (06978) announced that, starting from April 25, 2025: Xiao Hui has been appointed as a non-executive...
Immunotech Biopharm's 2024 Loss Narrows
Hong Kong Stock Announcement Gold Mining | CHINA OVERSEAS reported annual performance with a profit attributable to Shareholders of 15.636 billion yuan, a decrease of 38.95% year-on-year.
FOSUN PHARMA (02196) plans to invest 0.27 billion yuan to subscribe for UnitedHealth insurance's 0.105 billion newly issued shares; Keji Pharmaceuticals-B (02171): A summary of the research results for ShuRuiJia'O LunSai injection has been accepted for oral presentation at the 2025 ASCO Annual Meeting.